Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017
On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).
In 2016, AstraZeneca (AZN) reported research and development (or R&D) expenses of around $5.6 billion.
In 2016, AstraZeneca’s (AZN) poly ADP-ribose polymerase (or PARP) inhibitor, Lynparza, managed to report revenues close to $218 million.
Mylan’s Key Developments and Big Plans: What You Should Know
The recent developments reported by Mylan (MYL) include commercial developments and product developments. Let’s take a closer look.
Mylan (MYL) reported an increase of 17% in revenues at ~$2.2 billion in 1Q16 from $1.9 billion in 1Q15.
The specialty segment reported an increase of 17% in revenues at $247.9 million in 1Q16 versus $211.1 million in 1Q15.
OptumCare Expected to Become Key Growth Driver for UnitedHealth
As OptumCare continues to branch out across multiple markets, it may have a favorable impact on reducing UnitedHealth Group’s medical care ratio.
In its bid to control healthcare costs, UnitedHealth Group’s (UNH) OptumRx segment has been actively deploying data analytics across its Optum platform.
UnitedHealth Group’s (UNH) Optum One is being used by about 700 hospitals and 7,000 medical clinics, which together cover about 140,000 healthcare providers.
Molina Healthcare: Why Molina’s revenues have been growing fast
Molina Healthcare, Inc. (MOH): Revenue growth In general, Medicaid health plans grow revenue by increasing their membership or generating higher rates from state governments. The latter portion is often left up…
Investor day could provide a positive update to long-term growth MOH has been under pressure of late, without much reason. After beating 2Q consensus EPS estimates, even after including roughly…
Molina Healthcare, Inc. (MOH): Market overview Medicaid is a rapidly growing segment within healthcare, which should directly benefit MOH. In addition to typical market growth of mid-single digits, there are several…
Yellen’s Caution Led Battered Healthcare Up 1.2% on March 29
With the Fed stressing caution, investor sentiment turned toward the utilities and healthcare sectors, which rose 1.5% and 1.2%, respectively, on March 29.
Henry Schein reported 3Q15 net sales of $2,685.8 million, a rise of 2.4% compared to the net sales of $2,623.7 million in fiscal 3Q14.
The Health Care Select Sector SPDR ETF (XLV) has by and large been an outperformer in 2015. It has returned 5.1% on a YTD (year-to-date) basis.
How Could Trump’s Presidency Affect Hospitals and Insurance?
The effects of repealing Obamacare Donald Trump is definitely not in favor of the Affordable Care Act, known as Obamacare. As he wants to repeal the act completely and replace it…
While the recent trade cases have buoyed the US steel industry, Europe is still weak. A major recovery in U.S. Steel’s Europe earnings looks elusive in the near-term.
Wall Street analysts have projected that Universal Health Services’ net profit margin will increase marginally from 7.5% in 2015 to 7.6% in 2016.
Healthcare Assets are a Lucrative Target
A highly lucrative target But chronic underspending by providers and ease of access to their networks only partially accounts for the rise of healthcare system cyber attacks. The healthcare sector…
Throughout the current cycle, the healthcare sector has been a major source of growth for both the economy and investors. Over the past five years, healthcare expenditure has outpaced U.S.…
In 4Q15, Danaher’s (DHR) adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) was ~$1.4 billion, while its EBITDA margin was 23.3%.
Failed Healthcare Bill Will Impact the Pharmaceutical Industry
Due to the failure of the new healthcare bill, major pharmaceutical companies witnessed a fall in their share prices from March 23, 2017, to March 27, 2017.
The healthcare bill’s failure had a negative impact on investor sentiment for health insurance carriers.
Trumpcare’s failure is considered to be a boon by hospital companies treating a significant portion of Medicaid members.